ID: ALA4062485

Max Phase: Preclinical

Molecular Formula: C25H43N3O2

Molecular Weight: 417.64

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  CCCCCCCCCCCCCCc1nc(OC2CCC2)nc(N2CCC2)c1O

Standard InChI:  InChI=1S/C25H43N3O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-18-22-23(29)24(28-19-15-20-28)27-25(26-22)30-21-16-14-17-21/h21,29H,2-20H2,1H3

Standard InChI Key:  VQQBCIISDVGLQM-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 417.64Molecular Weight (Monoisotopic): 417.3355AlogP: 6.57#Rotatable Bonds: 16
Polar Surface Area: 58.48Molecular Species: NEUTRALHBA: 5HBD: 1
#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: 9.74CX Basic pKa: 6.27CX LogP: 7.94CX LogD: 7.90
Aromatic Rings: 1Heavy Atoms: 30QED Weighted: 0.31Np Likeness Score: -0.06

References

1. Chevalier A, Khdour OM, Schmierer M, Bandyopadhyay I, Hecht SM..  (2017)  Influence of substituent heteroatoms on the cytoprotective properties of pyrimidinol antioxidants.,  25  (5): [PMID:28189395] [10.1016/j.bmc.2017.01.030]

Source